Banca de DEFESA: JULLIANA DANIELLE NASCIMENTO DE VERAS

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : JULLIANA DANIELLE NASCIMENTO DE VERAS
DATE: 10/07/2023
TIME: 14:00
LOCAL: Sala virtual - https://meet.google.com/ehz-hwyo-qin
TITLE:

VACCINATION AGAINST HEPATITIS B IN CHRONIC RENAL PATIENTS BEFORE OR AFTER HEMODIALYSIS TREATMENT: A RANDOMIZED  PILOT CLINICAL TRIAL

KEY WORDS:

Vaccination, Hepatitis B, Chronic renal failure, hemodialysis, Randomized Controlled Trial

PAGES: 99
BIG AREA: Ciências da Saúde
AREA: Enfermagem
SUMMARY:

Introduction: The control of the spread of hepatitis B virus infection in the dialysis population has been an important goal in the management of end-stage renal disease, due to exposure to blood products and compromised immune status.  Despite a decrease in the incidence of HBV infection and these patients usually show an impaired immune response to the hepatitis B virus vaccine Objective: To compare the increase in titration of antibodies against Hepatitis B conferred by vaccination before or after hemodialysis Material and method: This is a quantitative research with an experimental approach,  interventional, randomized clinical trial (RCT), conducted with people undergoing hemodialysis treatment in the age group between 18 and 40 years using the Hepatitis B vaccine. The hypotheses were tested by comparing two groups of individuals simultaneously: The : distinction occurred with the participants divided into two groups: one experimental and one control; and for the experimental group, receiving the intervention of interest were the patients submitted to the hepatitis B vaccine before the hemodialysis procedure and the control group were the patients submitted to the vaccine after hemodialysis, standard therapy to the intervention.  The study was approved by the Research Ethics Committee by means of a favorable opinion under nº 5.340.073 under the protocol CAAE- 55210822.0.0000.5013, as well as by ReBEC, with approval ID RBR-9vvb89s. Results: The study included 25 people with a mean age of 29.88 years (SD ± 6.45). The experimental group had 12 participants (48%) and 13 people in the control group (52%). All participants achieved antibody titers (≥ 10 mIU/mL), with mean anti-Hbs IgG of 674.92 mIU/mL (SD ±369.22) after the entire intervention. The Experimental group obtained a higher mean titration of anti-HBs antibodies (763.08 mIU/mL) compared to the control group (593.55 mIU/mL). There was no influence of the variables gender, color, education, underlying disease, blood type, RH factor, alcohol use and presence of anemia, BMI, duration of session, blood flow and months of hemodialysis. Conclusion: This clinical trial indicates that there is a tendency to achieve hepatitis B antibody titre prior to hemodialysis.

BANKING MEMBERS:
Presidente - 1924449 - EVELINE LUCENA VASCONCELOS
Interno(a) - 2022453 - PATRICIA DE CARVALHO NAGLIATE
Externo(a) à Instituição - ALFREDO DIAS DE OLIVEIRA FILHO - UFS